Year: 2022

SAMPO PLC                 STOCK EXCHANGE RELEASE         05/12/2022 at 10:30 pm Sampo plc’s share buybacks 05/12/2022 On 05/12/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  13,475 48.69 AQEU  28,953 48.70 CEUX  16,180 48.68 TQEX  62,373 48.69 XHELTOTAL 120,981 48.69  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...

WILMINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) will report its Fiscal 2023 first quarter results on January 4, 2023 before the market opens. The Company will also hold a conference call at 9:00 a.m. Eastern Time on January 4, 2023 to discuss its quarterly financial results, business highlights and outlook. In addition, the Company may answer one or more questions concerning business and financial developments and trends, the Company’s view on earnings forecasts and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed. A simultaneous live webcast of the call and replay will be available over the Internet at http://investors.unifirst.com. Headquartered in Wilmington, Mass., UniFirst Corporation...

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response rate Achieved 100% complete remission in patients with an objective response rate Long-term safety and durable response are demonstrated in patients who continued on treatment for over a yearSAN DIEGO, Dec. 05, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) (Seongnam, South Korea). ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento....

Two Young Entrepreneurs Bet on NFTs and Select WISe.Art Marketplace to Sale Their New Series of NFT Watches Geneva, Madrid – December 5, 2022 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, AI, Blockchain and IoT company, today announced that its 3.0 NFT Marketplace WISe.ART will create a series of NFTs for watches connecting owners with their WISeID. WISeID is a trusted identity service provided by WISeKey that enables access to the web and mobile applications with strong authentication techniques. Eduardo Beltrà Ferre and José Gutierrez Blanco will soon release the brand-new series of NFT watches designed by renowned artist Pedro Sandoval, master of the art of animated video making who is one of the WISe.ART NFT platform’s early adopters. They chose to elect WISe.ART...

Today Kvika banki hf. sold nominal ISK 560 million in the bond series KVIKA 25 1201 GB at the price of 100.00, a 1.25% spread over the 3M REIBOR interest rate. The bonds have a maturity of 3 years and pay interest quarterly. Following the tap issuance, the total amount issued in the series will be ISK 1,660 million. The bonds are expected to be issued and admitted to trading on Nasdaq Iceland’s sustainable debt market on 8 December 2022. The bonds will be issued under the bank’s domestic debt programme with reference to its green financing framework. For further information please contact Kvika‘s investor relations at ir@kvika.is or via tel. (+354) 540 3200.

Monies RAISED in the Community STAY in the Community LAS VEGAS, Dec. 05, 2022 (GLOBE NEWSWIRE) — Tough Enough to Wear Pink™ (TETWP), the Western Community’s grassroots campaign to raise awareness and funds for breast cancer returns to Las Vegas’s Thomas & Mack Center to celebrate the 18th annual Tough Enough to Wear Pink Night. Since its inception, the ten-day rodeo championship has raised life-altering funds for the cause. “This year, we have fundraised $39 million to date,” shares Lacey Wheatley, Executive Director of Tough Enough to Wear Pink. “We are excited to have the honor of announcing our top fundraising rodeos of the year and recognizing sponsors, volunteers and fans for their support.” The arena promises to be a sea of pink, with rodeo athletes and fans sporting the color in honor of breast cancer awareness....

Point d’avancement au titre du contrat de financement avec European High Growth Opportunities Securitization Fund Rappel du contexte NEOLIFE (Euronext Growth Paris – Code ISIN FR0011636083 – Mnémonique ALNLF) (la « Société ») a signé début juillet 2022 un contrat de financement avec le fonds d’investissement luxembourgeois European High Growth Opportunities Securitization Fund (l’« Investisseur »). Cette ligne de financement flexible sur 18 mois, par émission de 400 bons d’émission d’obligations convertibles ou échangeables en actions nouvelles et/ou existantes d’une valeur nominale de 5.000 euros chacune (les « OCEANE »), se décompose en 8 tranches d’un montant nominal maximum de 250.000 euros, correspondant à l’émission d’un nombre maximum de 50 OCEANE chacune. Le montant nominal maximum total des OCEANE ainsi émises sera égal à 2...

COPENHAGEN, Denmark and BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announced that Mr. Nis Kruse joined the Company as EVP of Strategic Partnerships and General Manager of EMEA & APAC. He will also serve as site leader for the Hellerup, Denmark office. “We are preparing for the prospective global launch of NGAL tests, having submitted our De Novo application to the US Food and Drug Administration to aid in identifying pediatric patients at risk of moderate to severe Acute Kidney Injury (AKI),” said Tony Pare, BioPorto’s CEO. “Nis’ experience in strategic partnership development, distributor management, and building commercial teams will be a welcome addition to the BioPorto executive team.” Mr. Kruse most recently served as SVP & Chief Commercial Officer at SSI Diagnostica...